From PTEN loss of expression to RICTOR role in smooth muscle differentiation: Complex involvement of the mTOR pathway in leiomyosarcomas and pleomorphic sarcomas

Modern Pathology

Volumn 25, Issue 2, 2012, Pages 197-211

  Gibault, Laure ^a,b,c,d,e   Ferreira, Céline ^a,b   Pérot, Gaëlle ^a,b   Audebourg, Anne ^e   Chibon, Frédéric ^f   Bonnin, Sarah ^a,b   Lagarde, Pauline ^f   Vacher Lavenu, Marie Cécile ^c,d,e   Terrier, Philippe ^g   Coindre, Jean Michel ^f   Aurias, Alain ^a,b  

^a INSTITUT CURIE   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e Institut Cochin   (France)

^f INSTITUT BERGONIÉ   (France)

^g INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

AKT; leiomyosarcoma; mTOR; mutation; PTEN; RICTOR; sarcoma

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN RICTOR; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHROMOSOME 10; COMPARATIVE GENOMIC HYBRIDIZATION; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; FIBROSARCOMA; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; LIPOSARCOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; SARCOMA; SMOOTH MUSCLE; TISSUE DIFFERENTIATION; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CARRIER PROTEINS; CELL DIFFERENTIATION; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; LIPOSARCOMA; MALE; MIDDLE AGED; MUSCLE, SMOOTH; PTEN PHOSPHOHYDROLASE; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE TUMOR; TISSUE ARRAY ANALYSIS; TOR SERINE-THREONINE KINASES;

EID: 84856529756     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.163     Document Type: Article

References (39)

1. Fletcher CD. The evolving classification of soft tissue tumors: an update based on the new WHO classification. Histopathology 2006;48:3-12.
2. Dei Tos AP. Classification of pleomorphic sarcomas: where are we now? Histopathology 2006;48:51-62.
3. Chibon F, Mariani O, Derré J, et al. A subgroup of malignant fibrous histiocytomas is associated with genetic changes similar to those of well-differentiated liposarcomas. Cancer Genet Cytogenet 2002;139:24-29. (Pubitemid 36120402)
4. Chibon F, Mariani O, Mairal A, et al. The use of clustering software for the classification of comparative genomic hybridization data. An analysis of 109 malignant fibrous histiocytomas. Cancer Genet Cytogenet 2003;141:75-78. (Pubitemid 36165199)
5. Coindre JM, Mariani O, Chibon F, et al. Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: a review of 25 cases initially diagnosed as malignant fibrous histiocytoma. Mod Pathol 2003;16:256-262. (Pubitemid 36337432)
6. Derré J, Lagacé R, Nicolas A, et al. Leiomyosarcomas and most malignant fibrous histiocytomas share very similar comparative genomic hybridization imbalances: an analysis of a series of 27 leiomyosarcomas. Lab Invest 2001;81:211-215. (Pubitemid 32176385)
7. Larramendy ML, Gentilec M, Soloneskib S, et al. Does comparative genomic hybridization reveal distinct differences in DNA copy number sequence patterns between leiomyosarcoma and malignant fibrous histiocytoma? Cancer Genet Cytogenet 2008;187:1-11.
8. Carneiro A, Francis P, Bendahl PA, et al. Indistinguishable genomic profiles and shared prognostic markers in undifferentiated pleomorphic sarcoma and leiomyosarcoma: different sides of a single coin? Lab Invest 2009;89:668-675.
9. Baird K, Davis S, Antonescu CR, et al. Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res 2005;65:9226-9235. (Pubitemid 41507988)
10. Francis P, Namløs HM, Mü ller C, et al. Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential. BMC Genomics 2007;8:73.
11. Nakayama R, Nemoto T, Takahashi H, et al. Gene expression analysis of soft tissue sarcomas: characterization and reclassification of malignant fibrous histiocytoma. Mod Pathol 2007;20:749-759. (Pubitemid 46933446)
12. Beck AH, Lee CH, Witten DM, et al. Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling. Oncogene 2010;29: 845-854.
13. Gibault L, Pérot G, Chibon F, et al. New insights in sarcoma oncogenesis: a comprehensive analysis of a large series of 160 soft tissue sarcomas with complex genomics. J Pathol 2011;223:64-71.
14. Bellacosa A, Kumar CC, Di Cristofano A, et al. Activation of AKT Kinases in Cancer: Implications for Therapeutic Targeting. Adv Cancer Res 2005;94: 29-86. (Pubitemid 41202364)
15. Sarbassov DD, Ali SM, Kim DH, et al. Rictor, a novel binding partner of mTOR, defines a rapamycininsensitive and raptor independent pathway that regulates the cytoskeleton. Curr Biol 2004;14: 1296-1302. (Pubitemid 38991819)
16. Sarbassov DD, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005;307:1098-1101. (Pubitemid 40262113)
17. Jiang BH, Liu LZ. PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res 2009;102:19-65.
18. Guertin DA, Stevens DM, Saitoh M, et al. mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 2009;15:148-159.
19. Pérot G, Derré J, Coindre JM, et al. Strong smooth muscle differentiation is dependent on myocardin gene amplification in most human retroperitoneal leiomyosarcomas. Cancer Res 2009;69:2269-2278.
20. Mandahl N, Fletcher CD, Dal Cin P, et al. Comparative cytogenetic study of spindle cell and pleomorphic leiomyosarcomas of soft tissues: A report from the CHAMP study group. Cancer Genet Cytogenet 2000; 116:66-73.
21. Hu J, Rao UN, Jasani S, et al. Loss of DNA copy number of 10q is associated with aggressive behavior of leiomyosarcomas: a comparative genomic hybridization study. Cancer Genet Cytogenet 2005;161: 20-27. (Pubitemid 41096047)
22. Meza-Zepeda LA, Kresse SH, Barragan-Polania AH, et al. Array comparative genomic hybridization reveals distinct DNA copy number differences between gastrointestinal stromal tumors and leiomyosarcomas. Cancer Res 2006;66:8984-8993. (Pubitemid 44521116)
23. Saito T, Oda Y, Kawaguchi K, et al. PTEN/MMAC1 gene mutation is a rare event in soft tissue sarcomas without specific balanced translocations. Int J Cancer 2003;104:175-178. (Pubitemid 36249792)
24. Kawaguchi K, Oda Y, Saito T, et al. Genetic and epigenetic alterations of the PTEN gene in soft tissue sarcomas. Hum Pathol 2005;36:357-363. (Pubitemid 40591805)
25. Di Cristofano A, Pesce B, Cordon-Cardo C, et al. Pten is essential for embryonic development and tumor suppression. Nat Genet 1998;19:348-355. (Pubitemid 28357906)
26. Di Cristofano A, De Acetis M, Koff A, et al. Pten and p27/KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet 2001;27:222-224. (Pubitemid 32157454)
27. Trotman LC, Niki M, Dotan ZA, et al. Pten dose dictates cancer progression in the prostate. PLoS Biology 2003;1:385-396.
28. Pallares J, Bussaglia E, Martínez-Guitarte JL, et al. Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities. Mod Pathol 2005;18:719-727. (Pubitemid 40676385)
29. Hernando E, Charytonowicz E, Dudas ME, et al. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med 2007;13: 748-753. (Pubitemid 46889749)
30. Chiang GG, Abraham RT. Targeting the mTOR signaling network in cancer. Trends Mol Med 2007;13:433-442. (Pubitemid 47570021)
31. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006;22:159-168.
32. Mack CP, Somlyo AV, Hautmann M, et al. Smooth muscle differentiation marker gene expression is regulated by RhoA-mediated actin polymerization. J Biol Chem 2001;276:341-347. (Pubitemid 32050325)
33. Posern G, Treisman R. Actin' together: serum response factor, its cofactors and the link to signal transduction. Trends Cell Biol 2006;16:588-596. (Pubitemid 44636222)
34. Villanueva A, Chiang DY, Newell P, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008;135:1972-1983.
35. Masri J, Bernath A, Martin J, et al. mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. Cancer Res 2007;67:11712-11720.
36. Italiano A, Kind M, Stoeckle E, et al. Temsirolimus in advanced leiomyosarcomas: patterns of response and correlation with the activation of the mammalian target of rapamycin pathway. Anticancer Drugs 2011;22: 463-467.
37. Chawla SP, Tolcher AW, Staddon AP, et al. Survival results with AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas: update of phase II trial [abstract]. J Clin Oncol 2006;24:521.
38. Okuno S, Mahoney M, Bailey H, et al. A multicenter phase 2 consortium (P2C) study of the mTOR inhibitor CCI-779 in advanced soft tissue sarcomas (STS) (abstract). J Clin Oncol 2006;24:521.
39. Dancey JE, Monzon J. Ridaforolimus: a promising drug in the treatment of soft-tissue sarcoma and other malignancies. Future Oncol 2011;7:827-839.